Загрузка...
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer
Until recently, patients with castration-resistant prostate cancer (CRPC) had limited therapeutic options once they became refractory to docetaxel chemotherapy, and no treatments improved survival. This changed in June 2010 when the Food and Drug Administration (FDA) approved cabazitaxel as a new op...
Сохранить в:
| Главные авторы: | , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Dove Medical Press
2011
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3063116/ https://ncbi.nlm.nih.gov/pubmed/21448449 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/DDDT.S13029 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|